Tag: Ketolide

First approved in 2004, Ketek (telithromycin) was a new class of antibiotic known as a ketolide, designed to combat resistance to older macrolide drugs. However, its history was marked by significant safety concerns, especially related to serious and sometimes fatal liver damage, which ultimately led to its removal from the market.

Developed over three decades of research, nafithromycin is a historic medical breakthrough as the first new antibiotic in its class to be introduced globally in over 30 years. This advanced ketolide is specifically designed to combat the growing threat of antimicrobial resistance, particularly in respiratory infections like pneumonia.

In recent years, the escalating threat of antimicrobial resistance has pushed pharmaceutical companies to innovate, leading to the development of powerful new antibiotics like nafithromycin. If you're wondering, "What is the brand name of nafithromycin?" the answer is Miqnaf, a breakthrough ketolide antibiotic created by the Indian pharmaceutical company Wockhardt. Launched to specifically address community-acquired bacterial pneumonia (CABP), Miqnaf represents a significant step forward in fighting drug-resistant infections.

In 2004, Ketek (telithromycin) received U.S. FDA approval as the first drug in a new class of antibiotics known as ketolides. This initial excitement was short-lived, however, as subsequent safety controversies led to its eventual withdrawal from the U.S. market.